Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.

Slides:



Advertisements
Similar presentations
Neoadjuvant therapy for Rectal cancer
Advertisements

Treatment.
Mammary ductal carcinoma
Advances and Emerging Therapy for Lung Cancer
Pulmonary Stereotactic Ablative Radiotherapy:
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Management of Colorectal Liver Metastasis
Esophageal Cancer, New updates in Chemoradiation Dr Hamid Reza Dehghan Manshadi Radiation Oncologist Iran University of Medical sciences.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Upper gastrointestinal cancers
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Resection For Lung Metastases M62 Coloproctology Course.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
CLINICAL TRIALS WITH BIOLOGICAL ENDPOINT IN ESOGASTRIC CANCER
Preoperative CCRT in Colorectal Cancer 嘉義長庚醫院 大腸直腸外科 葉重宏.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Neck Cancer Head and STATEMENTS ON January 28, 2006 Frankfurt am Main, Germany Surgery Management of Lymph Node Metastases.
Moderators: David Cort, MD Alex Denes, MD Panelists: Stephen Swisher, MD, PhD Edward Lin, MD.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Gastric Cancer Gidon Almogy MD Department of General Surgery Hadassah University Hospital.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
Prof. Francesco Boccardo University and National Cancer Research Institute of Genoa, Italy Prof. Francesco Boccardo University and National Cancer Research.
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
Gastric Cancer Resections in BC: How are we doing? Trevor D Hamilton MD FRCSC Surgical Oncology Network November 7, 2015.
RADIOTHERAPYin VULVAR CANCER 2013 ANZGOG Kailash Narayan.
Hormone treatment combined with radiotherapy
Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer Sofie De Craenea, Veerle Surmonta,b and Jan P. van Meerbeeck Current.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Adjuvant Radiation is Required for Gastric Cancer
Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!
Neoadjuvant Adjuvant Curative Palliative
What’s new in stage III lung cancer?
Presentation transcript:

Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery

Neoadjuvant therapy for esophageal carcinoma

Definition Neoadjuvant- a term used to describe preliminary cancer therapy (usually chemotherapy or radiation therapy) that precedes a necessary second modality treatment. ( Dorland ’ s Medical Dictionary 28 th edition p1106) Neoadjuvant- a term used to describe preliminary cancer therapy (usually chemotherapy or radiation therapy) that precedes a necessary second modality treatment. ( Dorland ’ s Medical Dictionary 28 th edition p1106)

The Role of Surgery No doubt that surgery remains the mainstay for curative treatment for carcinoma of esophagus No doubt that surgery remains the mainstay for curative treatment for carcinoma of esophagus Good at local control Good at local control –T1 tumor without lymph node after curative resection (confined to submucosa) survival up to 80% –T1/2 N0 :40% 5 yr survival –T3N0: 25% 5 yr survival

Limitation of Surgery Only % of cases are operable Only % of cases are operable Good at local control/ ??effectiveness in regional nodal control Good at local control/ ??effectiveness in regional nodal control

Limitation of surgery Once Lymph node involved 13%-15% survival only (varied with different specialist centers) Once Lymph node involved 13%-15% survival only (varied with different specialist centers) High chance of LN +ve 40-50% High chance of LN +ve 40-50% –T1 mucosal- 5% nodal met. –T1 submucosa- 25% nodal met.

Rationale for multi-modal therapy Local : downsizing effect ; so as to increase resectability Local : downsizing effect ; so as to increase resectability Regional: Decrease LN involvement which is an imminent poor prognostic factor Regional: Decrease LN involvement which is an imminent poor prognostic factor Systemic: Deal with micrometastasis Systemic: Deal with micrometastasis Synergistic effect of chemo& RT Synergistic effect of chemo& RT

Why neoadjuvant? Neoadjuvant versus Adjuvant Neoadjuvant versus Adjuvant –Better tolerance before major upper GI surgery (88% vs. 55 %) –Downstaging of tumor i.e. allowing surgery –May allow more conservative local control –Earliest means to tackle systemic spread

Disadvantages of neoadjuvant? Neoadjuvant versus Adjuvant Neoadjuvant versus Adjuvant –Over-treat / unnecessary exposure of systemic toxicity in patient with early tumor –Delay surgical treatment –?increase surgical mortality/morbidity

Neoadjuvant therapy- questions to answer ?Survival benefit/disease-free survival ?Survival benefit/disease-free survival ?Increase resectability/?downsizing ?Increase resectability/?downsizing ?Decrease lymph-node met. ?Decrease lymph-node met. AdenoCA vs. SCC AdenoCA vs. SCC Early stage/late stage Early stage/late stage

Radiotherapy Most of the study do not show any benefit in terms of survival/resectability/ LN involvement Most of the study do not show any benefit in terms of survival/resectability/ LN involvement –Launois B et al. (81)N=124 –Gignoux et al (87) N= 229 –Huang GJ et al (87) N=360

Chemotherapy UK MRC study +ve trial N= 802 UK MRC study +ve trial N= 802 –R0( 60% vs. 54%) –Median survival 16.8 vs months P=0.004 –2 yrs survival 43% vs. 34% US 0113 – ve trial (+ve survival benefit in responder) N= 450 US 0113 – ve trial (+ve survival benefit in responder) N= 450 Conflicting results:? due to delay in surgery/toxicity for non – responder Conflicting results:? due to delay in surgery/toxicity for non – responder

Chemoradiotherapy Chemotherapy serve as radiosensitiser Chemotherapy serve as radiosensitiser Chemotherapy can reduce or eliminate micrometastasis Chemotherapy can reduce or eliminate micrometastasis

Meta-analysis of RCT on overall 3 yrs survival

Meta-analysis of RCT on downstaging effect

Meta-analysis of RCT on postop. mortality

Summary Pros: Neoadjuvant chemoradiotherapy downstaging the tumor Neoadjuvant chemoradiotherapy downstaging the tumor Increase resectability Increase resectability Longer disease free survival Longer disease free survival Much improved median survival in complete responder (up to 50 months median survival; 3 yr survival 64%) Much improved median survival in complete responder (up to 50 months median survival; 3 yr survival 64%)

Summary CONS no clear cut advantages in overall survival associated with higher operative mortality/morbidity ?over-treating the non-responder (up to 50-60%)

Unanswered question ? Any indicator for potential benefit of preop. chemoRT ? Any indicator for potential benefit of preop. chemoRT –?stage specific –?Histological type –?Genomic related

Perspective Non responder can up to % Non responder can up to % –Delay in operation –Higher operative mortality –Affect the overall survival of combined - modality treatment ?Response prediction ?Response prediction

Response prediction ?any significant prognostic and predictive marker ?any significant prognostic and predictive marker –Measuring of target molecule for which the chemo-agent works on eg: tumor thymidylate synthase, thymidine phosphorylase /chromosomal instabilty/p53 expression –Measuring the metabolic response: early interval PET scan